Molecular Correlates of Response to Apalutamide in nmCRPC and Androgen Annihilation Treatment Strategy with Abiraterone and Apalutamide in Chemo-Naïve mCRPC
June 04, 2026
Videos
PEER-TO-PEER CLINICAL CONVERSATIONS
Androgen Annihilation with Abiraterone and Apalutamide in Chemo-Naïve mCRPC - Final Results from ACIS
Dana Rathkopf, MD and Fred Saad, MD, FRCS
In this discussion, Dana Rathkopf and Fred Saad join Alicia Morgans to discuss the final results of the ACIS trial. The ACIS trial was designed to study is the combination of these two therapies, termed androgen annihilation, as first-line therapy in mCRPC in a chemotherapy-naive patient population.
Biological Signatures of Patients with Long-Term Responses to Apalutamide and Placebo in Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)
Felix Y. Feng MD
Alicia Morgans is joined by Felix Feng to discuss molecular determinants associated with response to apalutamide in patients who have nonmetastatic castration-resistant prostate cancer (nmCRPC).
The Progression-Free Survival to Overall Survival Connection. How to Interpret – and Why
Charles Ryan, MD
If a therapy in castrate-resistant prostate cancer (CRPC) shows an improvement in progression-free survival, but not overall survival, should that change practice? The topic is top of mind for us this month based on the results of the ACIS study presented at the ASCO GU 2021 Genitourinary Cancers Symposium by Dana Rathkopf of Memorial Sloan Kettering – Charles Ryan explores it here. To briefly recap, ACIS compared abiraterone to abiraterone plus apalutamide in men with chemotherapy naïve CRPC.
Final Results from ACIS, a Randomized, Placebo-Controlled Double-Blind Phase 3 Study of Apalutamide and Abiraterone Acetate plus Prednisone (AAP) Versus AAP in Patients with Chemo-Naive Metastatic Castration-Resistant Prostate Cancer
Dana E. Rathkopf, MD
Dana Rathkopf presents results of the ACIS trial assessing the combination of apalutamide + abiraterone acetate (two approved prostate cancer treatments with distinct receptor inhibition and ligand suppression actions, respectively) as compared to abiraterone acetate alone in patients with chemo-naive mCRPC.
Discussion: Molecular Correlates of Response to Apalutamide in nmCRPC and Final Results from ACIS, Androgen Annihilation with Abiraterone and Apalutamide in Chemo-Naïve mCRPC
Joshi J. Alumkal, MD
In this discussion, Joshi Alumkal discusses two presentations looking at molecular correlates of response to apalutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) and data from the ACIS trial of androgen annihilation with abiraterone and apalutamide in chemotherapy naïve mCRPC.
